CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2026)

CRISPR Therapeutics AG has disclosed Assets Average across 11 years of filings, most recently posting $2.5 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $2.5 billion, up 13.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 13.22% YoY), and the FY2025 annual result was $2.3 billion, up 0.8% from the prior year.
• Assets Average came in at $2.5 billion for Q1 2026 at CRISPR Therapeutics AG, up from $2.3 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $2.7 billion in Q1 2022 to a low of $2.1 billion in Q2 2025.
• The 5-year median for Assets Average is $2.3 billion (2025), against an average of $2.3 billion.
• Peak annual rise in Assets Average reached 41.53% in 2022, while the deepest fall reached 17.53% in 2022.
• CRISPR Therapeutics AG's Assets Average stood at $2.3 billion in 2022, then fell by 6.09% to $2.2 billion in 2023, then increased by 4.21% to $2.2 billion in 2024, then climbed by 0.28% to $2.3 billion in 2025, then increased by 10.65% to $2.5 billion in 2026.
• The last three Assets Average figures came in at $2.5 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.